Drug news
FDA Advisory Committee recommends Marqibo for Ph-ALL
Talon Therapeutics has announced the FDA Oncologic Drugs Advisory Committee voted 7 yes, 4 no, and 2 abstain that evidence from clinical studies supports a favorable benefit/risk assessment for use of Marqibo(vincristine sulfate liposomes injection) for the indication for the treatment of adult Philadelphia chromosome-negative (Ph-) Acute Lymphoblastic Leukemia (ALL) in second or greater relapse or that has progressed following two or more lines of anti-leukemia therapy. The FDA decision (PDUFA) date for Marqibo is May 13, 2012.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.
1 mins